Table 1 Demographic and clinical characteristics of the study population
From: A Metabolomics study of metabolites associated with the glomerular filtration rate
Variable | mGFR ≥ 90 ml/min per 1.73 m2 | 60 ≤ mGFR<90 ml/min per 1.73 m2 | 30 ≤ mGFR<60 ml/min per 1.73 m2 | mGFR<30 ml/min per 1.73 m2 | over all | P |
|---|---|---|---|---|---|---|
Sample size, | 37 | 39 | 47 | 22 | 145 | |
Age, y | 41.9(10.6) | 60.7(14.3) | 72.3(13.5) | 74.9.(17.0) | 61.8(18.6) | < 0.001 |
Male, % | 16(43.2) | 18(46.2) | 25(53.2) | 9(40.9) | 68(43.9%) | 0.736 |
Body mass index, kg/m2 | 23.6(13.7) | 24.7(4.5) | 24.5(5.2) | 24.1.(3.0) | 24.6(4.6) | 0.357 |
Diabetes prevalence, % | 4(10.8) | 7(17.9) | 11(23.4) | 10(45.5)) | 33(22.1) | 0.024 |
Hypertention prevalence, % | 4(10.8) | 15(38.4) | 28(59.6) | 15(68.2) | 62/(42.7) | < 0.001 |
Hyperuricemia prevalence, % | 4(10.8) | 6(15.4) | 10(21.3) | 5(22.7) | 25(17.2) | 0.524 |
Coronary artery disease prevalence, % | 2(5.4) | 5(12.8) | 11(23.4) | 9(40.9) | 27 (18.6) | 0.046 |
Lipid-lowering medication use, % | 2(5.4) | 6(15.3) | 5(10.6) | 2(9.1) | 15 (10.3) | 0.314 |
Uric acid-lowing medication use, % | 4(10.8) | 6(15.4) | 10(21.3) | 5(22.7) | 25(17.2) | 0.524 |
Antiplatelet drug use, % | 2(5.4) | 5((12.8) | 11(23.4) | 9(40.9) | 27 (18.6) | 0.023 |
Antihypertensive medication use, % | 4(10.8) | 15(38.4) | 28(59.6) | 15(68.2) | 62/(42.7) | < 0.001 |
glucose-lowering drug use, % | 4 (10.8) | 7(17.9) | 11(23.4) | 10(45.5)) | 33(22.1) | 0.024 |
Systolic BP, mmHg | 127.6(13.5) | 135(17.3) | 135.8(17.6) | 136.5(20.2) | 133.8(17.6) | 0.213 |
Diastolic BP, mmHg | 77.4(12.1) | 79.8(12.6) | 75.6(14.2) | 78.3(14.5) | 77.8(13.8) | 0.354 |
Creatinine | 0.82(0.4) | 1.2(0.8) | 1.9(2.1) | 4.2(2.6) | 1.85 (2.0) | < 0.001 |
Cystatin C | 0.83(0.81) | 1.3(0.6) | 1.8(0.5) | 3.2(1.3) | 1.27(1.2) | < 0.001 |
eGFRcr-cys, ml/min per 1.73 m2 | 103.1(16.2) | 75.5(23.2) | 49.3(17.1) | 23.2(12.1) | 66.1(32.7) | < 0.001 |
mGFR, ml/min per 1.73 m2 | 106.8(12.3) | 73.2(8.5) | 44.6(7.8) | 21.9(7.5) | 64.73(30.3) |